Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 42Stomach Neoplasms 8Neoplasm Metastasis 7Esophageal Neoplasms 7Colorectal Neoplasms 6Neoplasms 5HER2-positive Breast Cancer 5Lung Neoplasms 4Endometrial Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Trastuzumab × 90 days × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡